You are here
Pfizer Oncology Press Kit
PLEASE NOTE: All assets on this page are intended for use by U.S. media professionals only.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference on the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma. Pfizer Oncology is striving to change the trajectory of cancer.
For the latest information on our growing pipeline, product portfolio and collaborations with the broader cancer community, visit this page periodically for updates.
- Learn more and download an overview of our products pipeline and strategic approach.
- Learn more about Pfizer Oncology’s data presentations at American Society of Hematology (ASH) Annual Meeting
- Learn more about Pfizer Oncology’s data presentations at San Antonio Breast Cancer Symposium (SABCS)
- Learn how we’re advancing our science to deliver better patient care for the two million people impacted by breast cancer each year.
PFIZER ABSTRACT PLAIN LANGUAGE SUMMARIES (APLS) AT ASH and SABCS
To help interested non-scientists better understand the latest research, we are developing summaries in plain language for Pfizer research results presented at medical conferences. We call these “abstract plain language summaries” (APLS).